SEASONALITY STOCK REPORTS

[mick]

***** Genvec to develop new malaria vaccine for the U.S. Military (GNVC) 2.35 : Co announces that it has entered into a collaborative research and development agreement with the U.S. MilitaryMalaria Vaccine Program at the Walter Reed Army Institute of Research and the Naval Medical Research Center for the development andpre-clinical testing of a malaria vaccine candidate against Plasmodium vivax. More than 50% of malaria cases in US military personnel arecaused by P. vivax, which is debilitating upon primary infection and can causerecurrent illness years after infection occurs. This malaria strain has asignificant negative impact on world economic productivity and is a major threatto military preparedness.